Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

o. At 2 hours post-dose, 16.1% of patients taking ADX10059 were pain-free compared to 4.5% taking placebo (p = 0.039). A benefit of ADX10059 on migraine pain could be seen from 1 hour after dosing, with the compound being numerically superior to placebo at 1.0 and 1.5 hours post-dose. The magnitude of active versus placebo response at 2 hours (3.6 fold for pain-free and 1.6-fold for mild/no pain) was similar to that seen in the acute treatment migraine trials for the triptans (see ref. 1 below). In addition, there were trends to superiority for ADX10059 over placebo for migraine pain improvement (mild or no pain) at all time points up to two hours post-dosing. For other secondary efficacy endpoints there were no statistically significant differences between the two dose groups.

"The study results show an important and novel principle in the treatment of migraine with the positive outcome using an mGluR5 receptor modulator. The data offer the real prospect of development of a completely new class of medicines that modulate the effects of glutamate and thus offer a neural - nerve-based - therapy for migraine sufferers," commented Professor Peter Goadsby, Institute of Neurology, Queen Square London, and Department of Neurology, University of San Francisco, California.

"These results are the first demonstration of the involvement of mGluR5 in the migraine process," said Dr Vincent Mutel, CEO of Addex. "We believe that ADX10059 could play a significant role in the long term management of this disease, and have given the green light to initiate a Phase IIb trial."

About Migraine

Migraine is a condition characterized by recurrent episodes of headache accompanied by a variety of other symptoms such as nausea, light and sound sensitivity, and fatigue. Attacks may be preceded by aura (usually visual phenomena such as flashing lights, zigzag lines and loss of visual fields) in about 40% of patients. An average migraine patient suffers 12 attacks a y
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
(Date:3/27/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... the reporting of data from a single -center ... with the Delcath Hepatic Delivery System (Melphalan/HDS) and ... Society of Surgical Oncology (SSO) Annual Meeting 2015.  ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: SYUT ... a producer, marketer and seller of nutritional products for ... will present at Citi,s Greater China Investor Conference to ... Macau.  Management is currently scheduled to meet with institutional ...
... one of the leading clinical trial procurement companies, is ... Clinical Trials Supplies: The New GCPs - Good Clinical ... Coast Conference in Philadelphia, Pennsylvania at the Hilton Philadelphia ... on Wednesday October 20th, and a link to register ...
Cached Medicine Technology:Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference 2Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference 3
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for ... elbow injuries, according to new research released today at the ... Day. , “Our findings indicate that a 10 inch increase ... of a history of injury, a 10 mile per hour ... of a history of injury, and playing for more than ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
Breaking Medicine News(10 mins):Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... ... ... WASHINGTON , March 17 The following is a statement by ... , , ...
... , TAMPA, Fla. , March 17 ... features to enhance its acclaimed study program for the ... exams. Effective immediately, 30 animated muscle tutorials, 25 interactive study ... nationwide. These features, which include narration for auditory learners, further ...
... understanding of the Skp2 gene and its relation to cellular ... can suppress tumor development in common types of cancer, researchers ... and Memorial Sloan-Kettering Cancer Center report in the journal ... cycle regulation, cell proliferation, cell growth and the formation of ...
... potentially deadly infections long has focused on looking for ways ... University of Utah and Utah State University shows that modulating ... save more lives. In a study published March ... U of U cardiologist Dean Y. Li, M.D., Ph.D., professor ...
... an indicator of more serious disease, study finds , ... bowel syndrome (IBS) aren,t at increased risk for polyps, ... disease and, in most cases, don,t require a colonoscopy, ... 10 percent to 20 percent of Americans, include recurrent ...
... WHEATON, Ill. , March 17 ... Organizational Planning, John Brady , DHA, has been ... with Disabilities Task Force. The Task Force is responsible ... changes, recommendations, and innovations may be needed to enhance ...
Cached Medicine News:Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 2Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 2Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 5Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 6Health News:Disabling Skp2 gene helps shut down cancer growth 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Colonoscopy Not Needed for Most With Irritable Bowel Syndrome 2Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L)....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
For the quantitative determination of Glucose in serum. Endpoint Reaction Product measured at 520 nm. Linearity: 500 mg/dl....
For the quantitative determination of Glucose in serum. Endpoint reaction (NAD -> NADH) measured at 340 nm. Linearity: 600 mg/dl. Liquid working reagent prepared with simple 1:9 dilution....
Medicine Products: